Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Status: | Recruiting |
---|---|
Conditions: | Breast Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 2/22/2019 |
Start Date: | December 2013 |
Contact: | Cynthia Ma, MD, PhD |
Phone: | 314-362-9383 |
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
The study is being conducted to determine whether neoadjuvant endocrine therapy with
fulvestrant or the combination of anastrozole and fulvestrant, is better than anastrozole
when given before surgery to shrink the cancer and stop it from growing. Anastrozole inhibits
tumor growth by reducing the levels of estrogen and has been approved by the Food and Drug
Administration (FDA) of the United States for use after surgery for postmenopausal women with
estrogen receptor positive breast cancer. It is also considered a standard of care to give
anastrozole for a few months before surgery to shrink the tumor. Fulvestrant inhibits tumor
cell growth by reducing the levels of estrogen receptor in the tumor cell. It is not approved
by the FDA for use in women with early stage breast cancer before or after surgery, but is
approved by the FDA for patients with advanced (Stage 4) estrogen receptor positive breast
cancer that has spread to other parts of the body.
fulvestrant or the combination of anastrozole and fulvestrant, is better than anastrozole
when given before surgery to shrink the cancer and stop it from growing. Anastrozole inhibits
tumor growth by reducing the levels of estrogen and has been approved by the Food and Drug
Administration (FDA) of the United States for use after surgery for postmenopausal women with
estrogen receptor positive breast cancer. It is also considered a standard of care to give
anastrozole for a few months before surgery to shrink the tumor. Fulvestrant inhibits tumor
cell growth by reducing the levels of estrogen receptor in the tumor cell. It is not approved
by the FDA for use in women with early stage breast cancer before or after surgery, but is
approved by the FDA for patients with advanced (Stage 4) estrogen receptor positive breast
cancer that has spread to other parts of the body.
This clinical trial was designed to examine the pathologic outcomes of patients whose
neoadjuvant treatment course is determined using an early marker of endocrine resistance
(namely, Ki67 after 4 or 12 weeks of neoadjuvant therapy) as well as assessing clinical
outcome of patients whose disease burden after completing neoadjuvant endocrine therapy is
classified as Modified PEPI 0.
The primary and secondary objectives for the study are described below.
Primary Objectives:
1. To determine whether fulvestrant administered for 24 weeks as neoadjuvant endocrine
treatment decreases the proportion of endocrine resistant tumors* relative to patients
treated with anastrozole.
2. To determine whether fulvestrant in combination with anastrozole, administered for 24
weeks as neoadjuvant endocrine treatment, decreases the proportion of endocrine
resistant tumors* relative to patients treated with anastrozole.
3. To assess whether the 5 year RFS rate among women with a modified preoperative endocrine
prognostic index (PEPI) score of 0 following 24 weeks of neoadjuvant anastrozole
treatment is at least 95%.
4. To assess whether the 5 year RFS rate among women with a modified PEPI score of 0
following 24 weeks of neoadjuvant fulvestrant, or fulvestrant in combination with
anastrozole, is at least 95%. Note that this objective will only be tested if the
selected fulvestrant arm was shown to be superior to anastrozole in objective 1 or 2.
Endocrine resistant tumor is defined by any one of the following criteria*:
- Ki67> 10% after 4 weeks on neoadjuvant endocrine therapy
- Ki67> 10% after 12 weeks on neoadjuvant endocrine therapy
- Progressive disease is documented anytime during neoadjuvant endocrine therapy
- Surgical findings at 22-24 weeks post neoadjuvant endocrine therapy are such that:
- pT stage is 3/4
- positive lymph nodes are present or Ki67 > 2.7% (ie modified PEPI score of not
being 0)
- Discontinued neoadjuvant endocrine treatment for any reason
Secondary Objectives:
1. To assess whether the 5 year RFS rate among women with a preoperative endocrine
prognostic index PEPI score of 0 following 24 weeks of neoadjuvant anastrozole treatment
is at least 95%.
2. To examine the differences in surgical outcome, clinical and radiological response
rates, and safety profile between the fulvestrant arm and the anastrozole arm.
3. To examine the differences in surgical outcome, clinical and radiological response
rates, and safety profile between patients randomized to fulvestrant in combination with
anastrozole and those randomized to anastrozole.
4. To examine the rate of pathologic complete response (pCR) of 12 weeks of neoadjuvant
paclitaxel in patients with endocrine resistant disease following 4 weeks or 12 weeks of
neoadjuvant endocrine therapy (with either fulvestrant or anastrozole or the combination
of fulvestrant and anastrozole).
5. To examine the rate of pathologic complete response (pCR) among those patients with
endocrine resistant disease, following 4 weeks or 12 weeks of neoadjuvant endocrine
therapy (with either fulvestrant or anastrozole or the combination of fulvestrant and
anastrozole), who choose not to receive neoadjuvant paclitaxel, but another standard
neoadjuvant taxane and/or anthracycline containing regimen or CMF.
6. To summarize the frequency of severe (NCI CTCAE grade > 3) adverse events encountered
with administration of paclitaxel in the neoadjuvant setting.
7. To assess RFS for patients with endocrine resistant tumors defined as: 1) Ki67 > 10% at
week 4, 2) Ki67 > 10% at week 12 and 3) modified PEPI score of non-zero on neoadjuvant
endocrine therapy, with all three groups combined or separated.
neoadjuvant treatment course is determined using an early marker of endocrine resistance
(namely, Ki67 after 4 or 12 weeks of neoadjuvant therapy) as well as assessing clinical
outcome of patients whose disease burden after completing neoadjuvant endocrine therapy is
classified as Modified PEPI 0.
The primary and secondary objectives for the study are described below.
Primary Objectives:
1. To determine whether fulvestrant administered for 24 weeks as neoadjuvant endocrine
treatment decreases the proportion of endocrine resistant tumors* relative to patients
treated with anastrozole.
2. To determine whether fulvestrant in combination with anastrozole, administered for 24
weeks as neoadjuvant endocrine treatment, decreases the proportion of endocrine
resistant tumors* relative to patients treated with anastrozole.
3. To assess whether the 5 year RFS rate among women with a modified preoperative endocrine
prognostic index (PEPI) score of 0 following 24 weeks of neoadjuvant anastrozole
treatment is at least 95%.
4. To assess whether the 5 year RFS rate among women with a modified PEPI score of 0
following 24 weeks of neoadjuvant fulvestrant, or fulvestrant in combination with
anastrozole, is at least 95%. Note that this objective will only be tested if the
selected fulvestrant arm was shown to be superior to anastrozole in objective 1 or 2.
Endocrine resistant tumor is defined by any one of the following criteria*:
- Ki67> 10% after 4 weeks on neoadjuvant endocrine therapy
- Ki67> 10% after 12 weeks on neoadjuvant endocrine therapy
- Progressive disease is documented anytime during neoadjuvant endocrine therapy
- Surgical findings at 22-24 weeks post neoadjuvant endocrine therapy are such that:
- pT stage is 3/4
- positive lymph nodes are present or Ki67 > 2.7% (ie modified PEPI score of not
being 0)
- Discontinued neoadjuvant endocrine treatment for any reason
Secondary Objectives:
1. To assess whether the 5 year RFS rate among women with a preoperative endocrine
prognostic index PEPI score of 0 following 24 weeks of neoadjuvant anastrozole treatment
is at least 95%.
2. To examine the differences in surgical outcome, clinical and radiological response
rates, and safety profile between the fulvestrant arm and the anastrozole arm.
3. To examine the differences in surgical outcome, clinical and radiological response
rates, and safety profile between patients randomized to fulvestrant in combination with
anastrozole and those randomized to anastrozole.
4. To examine the rate of pathologic complete response (pCR) of 12 weeks of neoadjuvant
paclitaxel in patients with endocrine resistant disease following 4 weeks or 12 weeks of
neoadjuvant endocrine therapy (with either fulvestrant or anastrozole or the combination
of fulvestrant and anastrozole).
5. To examine the rate of pathologic complete response (pCR) among those patients with
endocrine resistant disease, following 4 weeks or 12 weeks of neoadjuvant endocrine
therapy (with either fulvestrant or anastrozole or the combination of fulvestrant and
anastrozole), who choose not to receive neoadjuvant paclitaxel, but another standard
neoadjuvant taxane and/or anthracycline containing regimen or CMF.
6. To summarize the frequency of severe (NCI CTCAE grade > 3) adverse events encountered
with administration of paclitaxel in the neoadjuvant setting.
7. To assess RFS for patients with endocrine resistant tumors defined as: 1) Ki67 > 10% at
week 4, 2) Ki67 > 10% at week 12 and 3) modified PEPI score of non-zero on neoadjuvant
endocrine therapy, with all three groups combined or separated.
Inclusion Criteria:
1. Female ≥18 years of age
2. Eastern Cooperative Oncology Group (ECOG) performance status 0-2
3. Postmenopausal, verified by:
- post bilateral surgical oophorectomy or
- no spontaneous menses ≥ 1 year or
- no menses for < 1 year with follicle-stimulating hormone (FSH) and estradiol
levels in postmenopausal range, according to institutional standards
4. Pathologic confirmation of invasive breast cancer diagnosed by core needle biopsy
5. Clinical T2-T4c, any N, M0 invasive breast cancer, by AJCC 7th edition clinical
staging, with the goal being surgery to complete excision of the tumor in the breast
and the lymph node. Primary tumor must be:
- palpable
- its largest diameters is at least 2.0 cm by physical examination or by
radiological assessment
Note:
- Patients with contralateral ductal carcinoma in situ and/or invasive breast
cancer are not eligible.
- Patients with multi-centric breast cancer (defined as more than one lesion is
invasive breast cancer in the same breast separated by ≥ 2 cm of normal breast
tissue are not eligible.
6. Invasive breast cancer is estrogen receptor positive with an Allred score of 6, 7 or 8
by local institution standard protocol. If an Allred Score is not reported on the
diagnostic pathology report, ER positivity in > 66% cells is eligible. If ER
positivity is ≤ 66%, the staining intensity (weak, intermediate, strong) is needed to
calculate the Allred Score to determine eligibility.
7. Invasive breast cancer is Human Epidermal Growth Factor Receptor 2 (HER2)- A patient
is considered to have HER2 negative breast cancer if one of the following applies:
- 0 or 1+ by immunohistochemistry (IHC) and ISH not done
- 0 or 1+ by IHC and ISH ratio (HER2 gene copy/chromosome 17) < 2
- 2+ by IHC and ISH ratio (HER2 gene copy/chromosome 17) < 2
8. Documentation of mammogram and ultrasound (including ductal carcinoma in situ (DCIS)
and invasive cancer) of the diseased breast performed within 56 days prior to
registration. Mammogram for the unaffected contralateral breast is required within 12
months prior to registration.
9. Laboratory values (≤ 14 days prior to registration):
1. Absolute Neutrophil Count (ANC) > 1000/mm^3
2. Platelet Count > 100,000/mm^3
3. Total Bilirubin < 1.5 x upper limits of normal (ULN)
4. Creatinine < 1.5 x ULN
5. Serum alanine transaminase (ALT) < 2.5 x ULN
10. Tissue acquisition: Patient must agree to provide the required research biopsies at
baseline, week 4 and at surgery for integral and integrated biomarker and correlative
studies.
Exclusion Criteria:
1. Premenopausal status
2. Inflammatory breast cancer defined as clinically significant erythema of the breast
and/or documented dermal lymphatic invasion (not direct skin invasion by tumor or peau
d' orange without erythema).
3. An excisional biopsy of this breast cancer.
4. Hormone replacement therapy of any type, megestrol acetate, or raloxifene within one
week prior to registration.
5. Tumor estrogen receptor (ER) Allred score between 0-5 or HER2 positive by IHC (3+) or
amplified by FISH > 2.0.
6. Surgical axillary staging procedure prior to study entry. Note: Fine needle aspiration
(FNA) or core needle biopsy of axillary node is permitted.
7. Clinical or radiographic evidence of metastatic disease. Metastatic workup is not
required, but is recommended for patients with clinical stage III disease. Note:
Isolated ipsilateral supraclavicular node involvement is permitted.
8. Breast implants are contraindicated only if the implant precludes the required
research biopsies or interferes with palpating the breast lesion.
9. Treatment for this cancer including surgery, radiation therapy, chemotherapy,
biotherapy, hormonal therapy or investigational agent prior to study entry.
10. History of invasive breast cancer or contralateral DCIS.
We found this trial at
852
sites
1234 West Napier Avenue
Saint Joseph, Michigan 49085
Saint Joseph, Michigan 49085
Principal Investigator: Kathleen J. Yost
Phone: 800-865-7884
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Zoneddy R. Dayao
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
Click here to add this to my saved trials
361 Old Belgrade Road
Augusta, Maine 04330
Augusta, Maine 04330
(207) 621-6100
Principal Investigator: Thomas H. Openshaw
Phone: 207-626-4855
Harold Alfond Center for Cancer Care MaineGeneral's Harold Alfond Center for Cancer Care (HACCC) is...
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
Bethlehem, Pennsylvania 18017
(484) 884-2200
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
Boston, Massachusetts 02115
(617) 732-5500
Principal Investigator: Jose P. Leone
Phone: 773-702-9171
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
Boston, Massachusetts 02215
617-667-7000
Principal Investigator: Daniel E. Morganstern
Phone: 877-442-3324
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Ellis G. Levine
Phone: 800-767-9355
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials
1 South Prospect Street
Burlington, Vermont 05401
Burlington, Vermont 05401
802-656-8990
Principal Investigator: Farrah B. Khan
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
Flint, Michigan 48503
(810) 262-9000
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
Click here to add this to my saved trials
524 South Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 341-7654
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
Las Vegas, Nevada 89102
(702) 383-2000
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
Los Angeles, California 90048
(1-800-233-2771)
Principal Investigator: Monica M. Mita
Phone: 310-423-8965
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
Richmond, Virginia 23298
(804) 828-0450
Phone: 804-828-9325
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Kristin A. Skinner
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Alison K. Conlin
Phone: 206-215-3086
Click here to add this to my saved trials
Click here to add this to my saved trials
Aberdeen, Washington 98520
Principal Investigator: Alison K. Conlin
Phone: 360-412-8958
Click here to add this to my saved trials
Click here to add this to my saved trials
Albuquerque, New Mexico 87110
Principal Investigator: Zoneddy R. Dayao
Phone: 505-559-6113
Click here to add this to my saved trials
Albuquerque, New Mexico 87109
Principal Investigator: Zoneddy R. Dayao
Phone: 505-272-0530
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Click here to add this to my saved trials
Anacortes, Washington 98221
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 773-702-9171
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 98508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99504
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Click here to add this to my saved trials
2000 E Greenville St
Anderson, South Carolina 29621
Anderson, South Carolina 29621
(864) 512-4640
Phone: 864-560-6812
AnMedical Health Cancer Center Cancer is the general term for a group of more than...
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
Antigo, Wisconsin 54409
Principal Investigator: Harish G. Ahuja
Phone: 715-623-9869
Click here to add this to my saved trials
Antioch, California 94531
Principal Investigator: Samantha A. Seaward
Phone: 877-642-4691
Click here to add this to my saved trials
921 North Oak Park Boulevard
Arroyo Grande, California 93420
Arroyo Grande, California 93420
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Asheville, North Carolina 28803
Principal Investigator: Raymond Thertulien
Phone: 828-650-8037
Click here to add this to my saved trials
Athens, Georgia 30607
Principal Investigator: Sharad A. Ghamande
Phone: 706-353-5006
Click here to add this to my saved trials
Auburn, California 95602
Principal Investigator: Oleg I. Krijanovski
Phone: 415-209-2686
Click here to add this to my saved trials
Auburn, California 95603
Principal Investigator: Oleg I. Krijanovski
Phone: 415-209-2686
Click here to add this to my saved trials
Augusta, Georgia 30912
Principal Investigator: Sharad A. Ghamande
Phone: 706-721-2388
Click here to add this to my saved trials
1303 D'Antignac Street
Augusta, Georgia 30901
Augusta, Georgia 30901
Principal Investigator: Sharad A. Ghamande
Phone: 773-702-9171
Click here to add this to my saved trials
Augusta, Georgia 30909
Principal Investigator: Sharad A. Ghamande
Phone: 706-736-1830
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
1501 S Potomac St
Aurora, Colorado 80012
Aurora, Colorado 80012
(303) 695-2600
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Medical Center of Aurora At The Medical Center of Aurora and Centennial Medical Plaza patients...
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
Aurora, Colorado 80045
720-848-0000
Principal Investigator: Virginia F. Borges
Phone: 720-848-0650
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Kendrith M. Rowland
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
Click here to add this to my saved trials
Austin, Texas 78702
Principal Investigator: Angel A. Rodriguez
Phone: 888-823-5923
Click here to add this to my saved trials
Austin, Texas 78705
Principal Investigator: Angel A. Rodriguez
Phone: 512-354-6391
Click here to add this to my saved trials
Austin, Texas 78705
Principal Investigator: Angel A. Rodriguez
Phone: 512-354-6391
Click here to add this to my saved trials
Austin, Texas 78759
Principal Investigator: Angel A. Rodriguez
Phone: 512-354-6391
Click here to add this to my saved trials
3325 Pocahontas Road
Baker City, Oregon 97814
Baker City, Oregon 97814
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
Ballwin, Missouri 63011
Principal Investigator: Jay W. Carlson
Phone: 314-251-7058
Click here to add this to my saved trials
2401 W Belvedere Ave
Baltimore, Maryland 21215
Baltimore, Maryland 21215
(410) 601-9000
Principal Investigator: Mayer Gorbaty
Phone: 410-601-6120
Sinai Hospital of Baltimore Sinai Hospital of Baltimore provides a broad array of high-quality, cost-effective...
Click here to add this to my saved trials
6701 N Charles St
Baltimore, Maryland 21204
Baltimore, Maryland 21204
(443) 849-2000
Principal Investigator: Robert B. Donegan
Phone: 443-849-3706
Greater Baltimore Medical Center The 255-bed medical center (acute and sub-acute care) is located on...
Click here to add this to my saved trials
Baltimore, Maryland 21218
Principal Investigator: Mahsa Mohebtash
Phone: 410-261-8151
Click here to add this to my saved trials
Baltimore, Maryland 21237
Principal Investigator: Mahsa Mohebtash
Phone: 443-777-7364
Click here to add this to my saved trials
Baltimore, Maryland 21239
Principal Investigator: Mahsa Mohebtash
Phone: 410-261-8151
Click here to add this to my saved trials
489 State St
Bangor, Maine 04401
Bangor, Maine 04401
(207) 973-7000
Principal Investigator: Thomas H. Openshaw
Phone: 207-973-4274
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
Click here to add this to my saved trials
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
Bardstown, Kentucky 40004
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
265 Fremont St
Battle Creek, Michigan 49017
Battle Creek, Michigan 49017
(269) 245-8166
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
Click here to add this to my saved trials
Bayamon, 00959
Principal Investigator: Luis Baez-Diaz
Phone: 787-395-7085
Click here to add this to my saved trials
Beachwood, Ohio 44122
Principal Investigator: Cynthia Owusu
Phone: 800-641-2422
Click here to add this to my saved trials
Click here to add this to my saved trials
3535 Pentagon Boulevard
Beavercreek, Ohio 45431
Beavercreek, Ohio 45431
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
2500 Bellevue Medical Center Drive
Bellevue, Nebraska 68123
Bellevue, Nebraska 68123
Principal Investigator: Elizabeth C. Reed
Phone: 402-559-6941
Click here to add this to my saved trials
Click here to add this to my saved trials
Bellingham, Washington 98225
Principal Investigator: Alison K. Conlin
Phone: 360-715-4133
Click here to add this to my saved trials
800 Farson Street
Belpre, Ohio 45714
Belpre, Ohio 45714
(740) 401-0417
Principal Investigator: Timothy D. Moore
Phone: 800-523-3977
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
Click here to add this to my saved trials
Bend, Oregon 97701
Principal Investigator: Alison K. Conlin
Phone: 541-706-2909
Click here to add this to my saved trials
Berkeley, California 94704
Principal Investigator: Oleg I. Krijanovski
Phone: 415-209-2686
Click here to add this to my saved trials
Berlin, Vermont 05602
Principal Investigator: Farrah B. Khan
Phone: 802-225-5400
Click here to add this to my saved trials
8901 Rockville Pike
Bethesda, Maryland 20889
Bethesda, Maryland 20889
(301) 295-4000
Principal Investigator: Jeremy G. Perkins
Phone: 301-319-2100
Walter Reed National Military Medical Center The Walter Reed National Military Medical Center is one...
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
Click here to add this to my saved trials
1233 North 30th Street
Billings, Montana 59101
Billings, Montana 59101
406-237-7000
Principal Investigator: Keren Sturtz
Phone: 406-969-6060
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
Click here to add this to my saved trials
Billings, Montana 59102
Principal Investigator: Keren Sturtz
Phone: 800-648-6274
Click here to add this to my saved trials
Birmingham, Alabama 35233
Principal Investigator: Erica M. Stringer-Reasor
Phone: 773-702-9171
Click here to add this to my saved trials
Bloomington, Illinois 61701
Principal Investigator: Nguyet A. Le-Lindqwister
Phone: 800-793-2262
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
Click here to add this to my saved trials
Boardman, Ohio 44512
Principal Investigator: Howard M. Gross
Phone: 330-629-7500
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Alison K. Conlin
Phone: 773-702-9171
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
Click here to add this to my saved trials
Bolivar, Missouri 65613
Principal Investigator: Rakesh Gaur
Phone: 800-328-6010
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: Bryan A. Faller
Phone: 314-996-5569
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Jose P. Leone
Phone: 877-442-3324
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
1100 Balsam Ave
Boulder, Colorado 80304
Boulder, Colorado 80304
(303) 440-2273
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Boulder Community Hospital Founded in 1922 as a community-owned and operated not-for-profit hospital, Boulder Community...
Click here to add this to my saved trials
Boulder, Colorado 80303
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
Click here to add this to my saved trials
Branson, Missouri 65616
Principal Investigator: Jay W. Carlson
Phone: 417-269-4520
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
Brewer, Maine 04412
Principal Investigator: Thomas H. Openshaw
Phone: 800-987-3005
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Brighton, Michigan 48114
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Brighton, Michigan 48114
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Click here to add this to my saved trials
Bronx, New York 10461
Principal Investigator: Della F. Makower
Phone: 718-379-6866
Click here to add this to my saved trials
Bronx, New York 10461
Principal Investigator: Della F. Makower
Phone: 718-379-6866
Click here to add this to my saved trials
Bronx, New York 10467
Principal Investigator: Della F. Makower
Phone: 718-379-6866
Click here to add this to my saved trials
Brooklyn, New York 11203
Principal Investigator: Iuliana Shapira
Phone: 718-613-8324
Click here to add this to my saved trials